Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
128
resultados
Última actualización
05/07/2025 [08:40:00]
Resumen de: WO2025141157A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: US2025213709A1
The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: EP4578401A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (Al) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the Al is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC-features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: WO2025136105A1
The invention relates to methods of predicting a response of an individual suffering from an inflammatory bowel diseases, such as Crohn's disease (CD) to treatment with a Tumor Necrosis Factor alpha inhibitor (TNFα-i). The invention further relates to anti-TNFα therapy, for treating an individual who was predicted to positively respond to said therapy by the methods of the invention, and to an integrin α4β7 blocking agent, or interleukin (IL)-12 and IL-23 blocking agent, for treating an individual who was predicted not to respond to anti-TNFα therapy by the methods of the invention.
Resumen de: US2025197388A1
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Resumen de: WO2025128818A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: NZ730490A
Described herein are methods and systems for distinguishing diarrhea predominant irritable bowel syndrome (D-IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: US2025191684A1
Example embodiments relate to identity-by-descent (IBD) relatedness based on focal and reference segments. An example method includes determining, by a services platform based on personal information of a focal individual, a focal string. The method also includes retrieving, by the services platform from a reference database, a reference string of a reference individual. Additionally, the method includes computationally identifying, by the services platform, IBD segments between the focal string and the reference string. Further, the method includes determining, by the services platform and based on the merged set of IBD segments, a degree of relatedness between the focal individual and the reference individual. In addition, the method includes providing, by the services platform, access to the degree of relatedness via a user interface.
Resumen de: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Resumen de: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Resumen de: CN113645846A
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: WO2025114553A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.The present invention also refers to an in vitro method for monitoring patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis; and/or for differentiating active patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis from those patients who are in remission.
Resumen de: US2020262889A1
Polypeptides comprising an amino acid sequence of Slc26a6 or IRBIT comprising a mutation that increases NaDC-1 binding, stability of the polypeptide, stability of NaDC-1 complex or a combination thereof are provided. Polypeptides comprising an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), comprising a mutation that increases succinate binding, stability of the polypeptide, stability of the mutSUCNR1-succinate complex or combinations thereof are also provided. Compositions comprising the polypeptides, nucleic acid molecules and vectors encoding the polypeptides, and methods of use of the polypeptides or compositions, specifically for treating succinate-associate diseases and conditions are also provided.
Resumen de: WO2025117950A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: US2025177779A1
In some embodiments, the present disclosure relates to a method. The method includes extracting a plurality of pre-treatment features from one or more first regions of interest (ROI) within pre-treatment imaging data. Prognostic pre-treatment features are identified from the plurality of pre-treatment features. The prognostic pre-treatment features are determinative of a treatment response. A plurality of post-treatment features are extracted from one or more second ROI within post-treatment imaging data. Prognostic post-treatment features are extracted from the plurality of post-treatment features. The prognostic post-treatment features are determinative of the treatment response. Prognostic tumor diversity features are determined from a common subset of the prognostic pre-treatment features and the prognostic post-treatment features. A machine learning stage is operated to generate a medical prediction of the treatment response for a bowel cancer patient using the prognostic tumor diversity features.
Resumen de: US2025180579A1
Methods for identifying sensitivity to what in an individual are provided, in which a sample from the individual is characterized for the presence of antibodies reactive with a whole wheat antigen and differentially characterizes for antibodies reactive with transglutaminase-2, transglutaminase-3, and transglutaminase-6. The presence of antibodies reactive with other wheat antigens, including α-gliadin, native γ-gliadin, native {acute over (ω)}-gliadin, and glutenin can also be characterized.
Resumen de: EP4564005A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.
Resumen de: WO2025109148A1
The invention relates to methods for diagnosing inflammatory bowel disease (IBD) and for distinguishing between common gastrointestinal disease (principally functional bowel disease/irritable bowel syndrome and coeliac disease) and IBD, especially in children and in subjects with normal levels of C-reactive protein. The methods are based on measuring the methylation level of at least one CpG site in at least one gene.
Resumen de: WO2025109034A1
The present invention relates to a method of determining or predicting the sensitivity of a subject to an anti-inflammatory treatment against IBD using vedolizumab, comprising the steps of: Providing a biological sample of a subject suffering from IBD, determining the methylation status of at least one CpG selected from the group consisting of cg08081727, cg17830959, cg03455316, cg05197062, cg00441209, cg00706914, cg12906381, cg25299227, cg05338672, cg17764313, cg16467921, cg04674762, cg02601475, cg14115807, cg21070860, cg04546413, cg12667521, cg05062694, cg02229781, cg17096289, cg08017465, cg18319102, cg09659072, cg03161606, cg25267487, and determining the sensitivity based on said methylation status wherein a higher level of methylation of cg17830959, cg03455316, cg25299227, cg05197062, cg12906381, cg05338672, cg02601475, cg00706914, cg04674762, cg02229781, cg09659072, cg08017465, cg18319102, cg21070860, cg14115807, and a lower level of methylation of cg08081727, cg00441209, cg17764313, cg16467921, cg05062694, cg25267487, cg03161606, cg04546413, cg17096289, cg12667521 in comparison to a control value or control sample is indicative of an increased sensitivity to a therapy using vedolizumab.
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: PH12022550223A1
Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.
Resumen de: EP4285988A2
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: US2025154215A1
The present invention relates to a dual PRR-inhibiting peptide system consisting of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9 and conjugated with a CT peptide for colon-specific delivery. In human-derived monocyte THP-1 and mouse bone marrow-derived macrophages (BMDMs), S100A8/A9-derived peptides including TLR4 and RAGE-interacting motifs inhibit the binding of S100 to TLR4 or RAGE and the activation of the NLRP3 inflammasome in a dose-dependent manner. When the peptide according to the present invention is injected into mouse models of acute and chronic colitis, survival is significantly increased, and pathological damage to the colon is alleviated. In a mouse model of colitis-related colorectal cancer, when the peptide according to the present invention is injected, body weight is increased, tumor burden in the distal colon is decreased, and histological colon damage is significantly alleviated. When the peptide according to the present invention is injected into an oxaliplatin-resistant CRC xenograft mouse model, EMT-associated markers are reduced in tumor tissues and tumor growth is significantly inhibited.
Nº publicación: US2025154591A1 15/05/2025
Solicitante:
AABO AKADEMI [FI]
\u00C5bo Akademi
Resumen de: US2025154591A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
BOPI
Sede Electrónica
